WO2016014992A3 - Compositions for treatment, diagnosis and prognosis of diseases - Google Patents
Compositions for treatment, diagnosis and prognosis of diseases Download PDFInfo
- Publication number
- WO2016014992A3 WO2016014992A3 PCT/US2015/042084 US2015042084W WO2016014992A3 WO 2016014992 A3 WO2016014992 A3 WO 2016014992A3 US 2015042084 W US2015042084 W US 2015042084W WO 2016014992 A3 WO2016014992 A3 WO 2016014992A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compositions
- treatment
- prognosis
- diseases
- diagnosis
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 238000004393 prognosis Methods 0.000 title abstract 2
- 206010061818 Disease progression Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000005750 disease progression Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
- C12Y207/01068—1-Phosphatidylinositol-4-phosphate 5-kinase (2.7.1.68)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Disclosed herein are novel pharmaceutically-useful compositions comprising an inhibitor of PIP5KIA, which compositions may be useful in the treatment of diseases such as cancer. Also disclosed is the use of the compositions for disease diagnosis and prognosis, treatment selection and disease progression monitoring.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462028783P | 2014-07-24 | 2014-07-24 | |
US62/028,783 | 2014-07-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2016014992A2 WO2016014992A2 (en) | 2016-01-28 |
WO2016014992A3 true WO2016014992A3 (en) | 2016-03-17 |
Family
ID=55163985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/042084 WO2016014992A2 (en) | 2014-07-24 | 2015-07-24 | Compositions for treatment, diagnosis and prognosis of diseases |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2016014992A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106544361A (en) * | 2016-12-02 | 2017-03-29 | 新乡医学院 | Mammalian cell expression vector, expression system, preparation method and application |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018223179A1 (en) | 2017-06-05 | 2018-12-13 | Immersive Robotics Pty Ltd | Digital content stream compression |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030114400A1 (en) * | 2001-12-06 | 2003-06-19 | Isis Pharmaceuticals Inc. | Antisense modulation of phosphatidylinositol-4-phosphate 5-kinase, Ialpha expression |
-
2015
- 2015-07-24 WO PCT/US2015/042084 patent/WO2016014992A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030114400A1 (en) * | 2001-12-06 | 2003-06-19 | Isis Pharmaceuticals Inc. | Antisense modulation of phosphatidylinositol-4-phosphate 5-kinase, Ialpha expression |
Non-Patent Citations (3)
Title |
---|
LI ET AL.: "The ATM Inhibitor KU-55933 Suppresses Cell Proliferation and Induces Apoptosis by Blocking Akt In Cancer Cells with Overactivated Akt.", MOL CANCER THER, vol. 9, no. 1, January 2010 (2010-01-01), pages 113 - 125 * |
MUSCOLINI ET AL.: "Phosphatidylinositol 4-Phosphate 5-Kinase alpha Activation Critically Contributes to CD 28-Dependent Signaling Responses.", THE JOURNAL OF IMMUNOLOGY, vol. 190, no. 10, 15 May 2013 (2013-05-15), pages 5279 - 5286 * |
VAN DEN BOUT ET AL.: "PIP5K-driven Ptdlns(4,5)P2 synthesis: regulation and cellular function.", J CELL SCI, vol. 122, no. 21, 1 November 2009 (2009-11-01), pages 3837 - 3850 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106544361A (en) * | 2016-12-02 | 2017-03-29 | 新乡医学院 | Mammalian cell expression vector, expression system, preparation method and application |
Also Published As
Publication number | Publication date |
---|---|
WO2016014992A2 (en) | 2016-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL264049A (en) | Compounds, compositions, and methods for the treatment of disease | |
WO2017030823A3 (en) | Anti-tigit antibodies | |
EP3448874A4 (en) | Compositions for the treatment of disease | |
EP3448875A4 (en) | Compositions for the treatment of disease | |
EP3448987A4 (en) | Compositions for the treatment of disease | |
EP3675859A4 (en) | Compounds, compositions, and methods for the treatment of disease | |
IL264156A (en) | Compounds, compositions, and methods for the treatment of disease | |
MX2022001105A (en) | Anti-tigit antibodies. | |
WO2016100985A3 (en) | Chimeric antigen receptors and methods of use thereof | |
EP3177732A4 (en) | Compositions and methods for the treatment of ophthalmic diseases and conditions | |
WO2015148863A3 (en) | Crispr/cas-related methods and compositions for treating sickle cell disease | |
WO2016098079A3 (en) | Compositions and methods for antibodies targeting bmp6 | |
MX2017009417A (en) | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof. | |
EP3182989A4 (en) | Methods and compositions for the prevention and treatment of disease | |
WO2015149034A3 (en) | Gene fusions and gene variants associated with cancer | |
CN106659716A8 (en) | Apilimod compositions and methods of use thereof | |
WO2015123449A3 (en) | Compositions and methods of using microrna inhibitors | |
WO2016106343A8 (en) | Probiotic organisms for diagnosis, monitoring, and treatment of inflammatory bowel disease | |
WO2015120372A3 (en) | Compositions and methods to inhibit ezh2 for the treatment of cardiovascular diseases | |
WO2015179835A3 (en) | Mit biomarkers and methods using the same | |
EP3149192A4 (en) | Methods and compositions for use of neutrophil elastase and proteinase 3 as diagnostic biomarkers | |
EP3218481A4 (en) | Biomarkers useful in the treatment of subjects having diseases of the eye | |
EP3137907A4 (en) | Methods and compositions for the diagnosis and treatment of kawasaki disease | |
MX382092B (en) | Heterocyclic compounds for the treatment of disease | |
WO2016094374A8 (en) | Compositions and methods for treatment of friedreich's ataxia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15824903 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15824903 Country of ref document: EP Kind code of ref document: A2 |